Although MEK/ERK inhibitors have been demonstrated to improve the progression‐free survival of patients with BRAF mutant melanoma, they failed to show similar activity in other solid tumors.[33] We propose that coinhibition of SP1/3 activity may enhance the inhibition of downstream target gene expression by disrupting ELK4‐SP1/3 complex formation. The gene discussed is MAPK1; the disease is melanoma.